Zydus reports positive Phase II(b) trial results for Saroglitazar Mg

Zydus reports positive Phase II(b) trial results for Saroglitazar Mg. Zydus Lifesciences announced positive topline results from its EVIDENCES-X Phase II(b) trial for Saroglitazar Mg in MASH patients. The drug showed improvement in liver histology and metabolic parameters, boosting near-term pipeline hopes. This success enhances regulatory prospects and may drive investor sentiment positively.

📊 STOCKS: $ZYDUSLIFE | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #ClinicalTrial